Lupus & antiphospholipid syndrome
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis
Authors' conclusion
Three years is the minimum duration of sCR protecting against development of IKF and damage accrual in patients with LN.
Study context
- Population
- Patients with biopsy-proven active lupus nephritis (LN) followed up at least twice yearlymedian follow-up 15.7 years
- Participants
- 293 patients
- Exposure
- Duration of sustained clinical remission vs never achieving sustained clinical remission (sCR)
- Outcome
- Minimum duration of sCR preventing damage accrual (SDI increase) and impaired kidney function (eGFR <60 mL/min/1.73 m² for at least 3 months)
Methodological detailslog-linear regression, time-dependent Cox proportional hazard model
- Log-linear regression
- Time-dependent Cox proportional hazard model
Main finding
As reported in the abstract
% change in SDI
−41.1%
P = 0.003
sCR ≥3 years
HR for IKF
0.10
P < 0.001
224 patients with ≥10 years of observation
Observational data: associations, not effects.
Further findings
| Outcome | sCR ≥3 years | Never sCR | P value |
|---|---|---|---|
| Increase in SDI at last observationNever sCR vs Ever sCR | — not stated in the abstract | median 2 (IQR 1–2.5) | P < 0.001 |
| IKF-free survival at 10, 20 and 25 years | 99%, 96%, and 91% | 87%, 68%, and 40% | P < 0.001 |
— not stated in the abstract
- Increase in SDI at last observation: Ever sCR median 1 (IQR 0–1.5)
Achievement of sCR
- Achieved sCR
- 84.3%
- Duration of sCR, years
- 8.7 (5.4-13.1)
IKF development (patients with ≥10 years of observation)
- Developed IKF
- 50 (22.3%)
- 224 patients
Original publication
Three years is the minimal effective duration of sustained clinical remission which prevents impaired kidney function and damage accrual in lupus nephritis. Ann Rheum Dis. Published 28 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →